GILEAD SCIENCES SL

The ADC market is projected to reach $47 billion by 2029, driven by cancer prevalence and precision medicine advancements, but toxicity remains a key challenge. Major players like Roche, Daiichi Sankyo, Pfizer, and Gilead lead innovation through collaborations, focusing on improving linker technologies, payload delivery, and antibody selectivity to mitigate adverse effects.

Echo IQ (ASX:EIQ) signed an integration agreement with top US cardiology hospital Beth Israel Deaconess Medical Center, leveraging its FDA-cleared AI-powered algorithm for heart disease detection. This deal, following FDA clearance, positions EIQ for significant industry exposure and potential revenue generation, with further hospital partnerships anticipated. EIQ's technology targets aortic stenosis and heart failure, with reimbursement from insurance companies forming its revenue model. The company is also in advanced negotiations with the prestigious Mayo Clinic for clinical validation of its heart failure product.

Gilead Sciences reports Livdelzi (seladelpar) Phase III study interim analysis showing 81% CBR in PBC patients, with 41% ALP normalisation and no treatment-related SAEs. The ASSURE trial, enrolling up to 500 PBC patients, highlights Livdelzi's long-term efficacy and safety, with decreasing adverse events over time.

T.C.-F.Y. advises and speaks for Gilead Sciences. G.L.-H.W. advises AstraZeneca, Gilead Sciences, GlaxoSmithKline, Janssen, Virion Biotherapeutics, speaks for Abbott, AbbVie, Ascletis, Bristol-Myers Squibb, Echosens, Ferring, Gilead Sciences, GlaxoSmithKline, Janssen, Roche, and received a research grant from Gilead Sciences.

Cassava Sciences appoints Freda Nassif as Chief Commercial Officer, positioning the company for commercial readiness ahead of Phase 3 trial results for Alzheimer's drug simufilam by end of 2024.

IDEAYA Biosciences appoints Stu Dorman as Chief Commercial Officer, leveraging his 20+ years of oncology commercialization experience from Gilead Sciences and Bristol Myers Squibb, including successful launches of Trodelvy® and Opdivo®.

Gilead Sciences announced 81% of PBC participants achieved durable biochemical response by Month 30 with Livdelzi, and 41% normalized ALP levels. Livdelzi also reduced pruritus severity, resolving itch in 27% of participants.

Nurix Therapeutics presented preclinical data for NX-5948 (oral BTK degrader) and GS-6791 (IRAK4 degrader, developed with Gilead Sciences) at ACR Convergence 2024, showing potential superiority over kinase inhibitors in inflammatory and autoimmune diseases.